Conserved sequence motifs and the structure of the mTOR kinase domain

Biochemical Society Transactions

Volumn 41, Issue 4, 2013, Pages 889-895

  Sauer, Evelyn ^a   Imseng, Stefan ^a   Maier, Timm ^a   Hall, Michael N ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Mammalian target of rapamycin (mTOR)

Indexed keywords

ADENOSINE TRIPHOSPHATE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME STRUCTURE; GENETIC CONSERVATION; HUMAN; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN SECONDARY STRUCTURE; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; CATALYTIC DOMAIN; CONSERVED SEQUENCE; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84880562113     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20130113     Document Type: Article

References (42)

1. Adams, J. A. (2003) Activation loop phosphorylation and catalysis in protein kinases: is there functional evidence for the autoinhibitor model? Biochemistry 42, 601-607
2. Ubersax, J.A. and Ferrell, J.E. (2007) Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol. Cell Biol. 8, 530-541
3. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934
4. Hanks, S.K. and Hunter, T. (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9, 576-596
5. Adams, J.A. (2001) Kinetic and catalytic mechanisms of protein kinases. Chem. Rev. 101, 2271-2290
6. Endicott, J.A., Noble, M.E. M. and Johnson, L.N. (2012) The structural basis for control of eukaryotic protein kinases. Annu. Rev. Biochem. 81, 587-613
7. Laplante, M. and Sabatini, D.M. (2012) mTOR signaling in growth control and disease. Cell 149, 274-293
8. Benjamin, D., Colombi, M., Moroni, C. and Hall, M.N. (2011) Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discovery 10, 868-880
9. Cornu, M., Albert, V. and Hall, M.N. (2013) mTOR in aging, metabolism, and cancer. Curr. Opin. Genet. Dev. 23, 53-62
10. Hung, C.-M., Garcia-Haro, L., Sparks, C.A. and Guertin, D.A. (2012) mTOR-dependent cell survival mechanisms. Cold Spring Harbor Perspect. Biol. 4, a008771
11. Zinzalla, V., Stracka, D., Oppliger, W. and Hall, M.N. (2011) Activation of mTORC2 by association with the ribosome. Cell 144, 757-768
12. Arencibia, J.M., Pastor-Flores, D., Bauer, A.F., Schulze, J.O. and Biondi, R.M. (2013) AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochim. Biophys. Acta 1834, 1302-1321
13. Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M.H., Rüegg, M.A. and Hall, M.N. (2012) Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab. 15, 725-738
14. Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J.L., Bonenfant, D., Oppliger, W., Jenoe, P. and Hall, M.N. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457-468
15. Kim, D.-H., Sarbassov, D.D., Ali, S.M., Latek, R.R., Guntur, K.V., Erdjument-Bromage, H., Tempst, P. and Sabatini, D.M. (2003) GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 11, 895-904
16. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J. and Yonezawa, K. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189
17. Kim, D.-H., Sarbassov, D.D., Ali, S.M., King, J.E., Latek, R.R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D.M. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163-175
18. Schalm, S.S. and Blenis, J. (2002) Identification of a conserved motif required for mTOR signaling. Curr. Biol. 12, 632-639
19. Schalm, S.S., Fingar, D.C., Sabatini, D.M. and Blenis, J. (2003) TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13, 797-806
20. Wullschleger, S., Loewith, R., Oppliger, W. and Hall, M.N. (2005) Molecular organization of target of rapamycin complex 2. J. Biol. Chem. 280, 30697-30704
21. Sarbassov, D.D., Ali, S.M., Kim, D.H., Guertin, D.A., Latek, R.R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D.M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302
22. Pearce, L.R., Huang, X., Boudeau, J., Paw?owski, R., Wullschleger, S., Deak, M., Ibrahim, A.F., Gourlay, R., Magnuson, M.A. and Alessi, D.R. (2007) Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J. 405, 513-522
23. Lempiäinen, H. and Halazonetis, T.D. (2009) Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 28, 3067-3073
24. Knutson, B.A. (2010) Insights into the domain and repeat architecture of target of rapamycin. J. Struct. Biol. 170, 354-363
25. Andrade, M.A. and Bork, P. (1995) HEAT repeats in the Huntington's disease protein. Nat. Genet. 11, 115-116
26. Blatch, G.L. and Lässle, M. (1999) The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. BioEssays 21, 932-939
27. Andrade, M.A., Perez-Iratxeta, C. and Ponting, C.P. (2001) Protein repeats: structures, functions, and evolution. J. Struct. Biol. 134, 117-131
28. Choi, J., Chen, J., Schreiber, S.L. and Clardy, J. (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239-242
29. Dames, S.A., Mulet, J.M., Rathgeb-Szabo, K., Hall, M.N. and Grzesiek, S. (2005) The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability. J. Biol. Chem. 280, 20558-20564
30. Yang, H., Rudge, D.G., Koos, J.D., Vaidialingam, B., Yang, H.J. and Pavletich, N.P. (2013) mTOR kinase structure, mechanism and regulation. Nature 497, 217-223
31. Sturgill, T.W. and Hall, M.N. (2009) Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCα. ACS Chem. Biol. 4, 999-1015
32. Nowak, P., Cole, D.C., Brooijmans, N., Bursavich, M.G., Curran, K.J., Ellingboe, J.W., Gibbons, J.J., Hollander, I., Hu, Y., Kaplan, J. et al. (2009) Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase. J. Med. Chem. 52, 7081-7089
33. Pacold, M.E., Suire, S., Perisic, O., Lara-Gonzalez, S., Davis, C.T., Walker, E.H., Hawkins, P.T., Stephens, L., Eccleston, J.F. and Williams, R.L. (2000) Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ . Cell 103, 931-943
34. Liu, Q., Wang, J., Kang, S.A., Thoreen, C.C., Hur, W., Ahmed, T., Sabatini, D.M. and Gray, N.S. (2011) Discovery of 9-(6-aminopyridin-3-yl)-1-(3- (trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J. Med. Chem. 54, 1473-1480
35. Jiang, X., Sun, Y., Chen, S., Roy, K. and Price, B.D. (2006) The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM. J. Biol. Chem. 281, 15741-15746
36. Sun, Y., Xu, Y., Roy, K. and Price, B.D. (2007) DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol. Cell. Biol. 27, 8502-8509
37. Baker, D. and Sali, A. (2001) Protein structure prediction and structural genomics. Science 294, 93-96
38. John, B. and Sali, A. (2003) Comparative protein structure modeling by iterative alignment, model building and model assessment. Nucleic Acids Res. 31, 3982-3992
39. Jain, E., Bairoch, A., Duvaud, S., Phan, I., Redaschi, N., Suzek, B.E., Martin, M.J., McGarvey, P. and Gasteiger, E. (2009) Infrastructure for the life sciences: design and implementation of the UniProt website. BMC Bioinf. 10, 136
40. Edgar, R.C. (2004) MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinf. 5, 113
41. Waterhouse, A.M., Procter, J.B., Martin, D.M.A., Clamp, M. and Barton, G.J. (2009) Jalview version 2: a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189-1191
42. Gouet, P., Robert, X. and Courcelle, E. (2003) ESPript/ENDscript: extracting and rendering sequence and 3D information from atomic structures of proteins. Nucleic Acids Res. 31, 3320-3323